DT
Precision BioSciences, Inc.
DTIL · NASDAQ
$6.67 +0.15% (+$0.01)
1M -21.07%
Market Cap $85.6M
P/E Ratio -
Div. Yield -
ROE 91.60%
Bulios Fair Price
$8.5
27.4% upside
Current Price
$6.67
Undervalued Fair Value Overvalued
According to Bulios Fair Price, DTIL is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
84 /100
Cheap P/B 1.89x
P/S 1.90x
P/FFO N/A
Growth
77 /100
Growing Book val. growth 15.14%
Rev. growth 10.93%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 80.78%
Gross margin 100.00%
FCF margin 115.48%
Quality
5 /100
Poor ROA 41.88%
ROIC 30.23%
Asset turnover 0.36x
Debt
57 /100
Moderate Int. coverage -39.59x
Debt/Equity 0.62x
Current ratio 12.82x
Stability
15 /100
Unstable EPS volatility 307.73%
Beta 1.25x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about DTIL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Amoroso
Employees
67
Headquarters
Durham
Upcoming events
02 NOV
Earnings
Upcoming earnings report